Salvatore Napoli, MD
Neurology · Foxboro, MANPI 1588715882
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $489,595 of the $612,882 with a category attached, or 79.9%. It is spread thinly across 60 manufacturers, the largest accounting for just 22.9%. Reporting peaked in 2019 at $131,811 and has fallen 57.6% since, to $55,859 in 2025. Among neurology clinicians in MA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,242 payments — averaging $493.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biogen$140K
- EMD Serono, Inc.$109K
- Sanofi$59K
- Eisai Inc.$47K
- E.r. Squibb & Sons, L.L.C.$40K
- Novartis$37K
- plus $180K from 54 others
Across 468 payments — averaging $5636.03 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$912K
- TG Therapeutics, Inc.$383K
- EMD Serono, Inc.$205K
- Genentech, Inc.$195K
- Ipsen Innovation$154K
- E.r. Squibb & Sons, L.L.C.$140K
- plus $648K from 14 others
What the payments were for
- Consulting fees$75,30812%
- Speaking & faculty fees$489,59580%
- Travel & lodging$21,0763%
- Food & beverage$26,5954%
- Education$3080%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$612,882 in reported general payments places this provider in the 95th percentile of 761 neurology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Kesimpta PenOfatumumab | 81 | $713,129 |
| AubagioTeriflunomide | 59 | $648,554 |
| OcrevusOcrelizumab | 12 | $470,511 |
| CopaxoneGlatiramer Acetate | 52 | $288,515 |
| TysabriNatalizumab | 34 | $283,992 |
| AmpyraDalfampridine | 44 | $228,000 |
| Avonex (4 Pack)Interferon Beta-1a | 19 | $151,289 |
| Avonex Pen (4 Pack)Interferon Beta-1a | 18 | $143,988 |
| VumerityDiroximel Fumarate | 14 | $118,432 |
| RebifInterferon Beta-1a/Albumin | 11 | $112,968 |
| GlatopaGlatiramer Acetate | 29 | $101,827 |
| Dalfampridine ErDalfampridine | 190 | $89,668 |
| VyeptiEptinezumab-Jjmr | 18 | $85,426 |
| Gammagard LiquidImmun Glob G(Igg)/Gly/Iga Ov50 | 11 | $73,417 |
| Teriflunomide | 28 | $61,615 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| SanofiAubagio | $58,984 | $648,55459 claims |
| BiogenTysabri, Avonex (4 Pack), Vumerity | $140,230 | $553,71367 claims |
| Genentech, Inc.Ocrevus | $1,281 | $470,51112 claims |
| Teva Pharmaceuticals USA, Inc.Copaxone | $147 | $288,51552 claims |
| Acorda Therapeutics, IncAmpyra | $192 | $228,00044 claims |
| EMD Serono, Inc.Rebif | $109,474 | $112,96811 claims |
| Lundbeck LLCVyepti | $3,151 | $85,42618 claims |
| AbbVieBotox, Qulipta | $1,064 | $37,30032 claims |
| PfizerNurtec Odt | $448 | $35,80522 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 761 neurology providers in Massachusetts.
Other neurology in Foxboro
- Christopher WrightBoston$2.5M
- Shivang JoshiWestborough$1.2M
- Egilius SpieringsWellesley Hills$680K
- Thomas ScammellBoston$617K
- Alfred SandrockBoston$490K
- Joshua KatzWellesley$462K
- Guy BuckleBrookline$450K
- Pushpa NarayanaswamiBoston$420K
- Kenneth GorsonWellesley$414K
- Roy FreemanBoston$390K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.